Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (6)
  • Open Access

    ARTICLE

    Identification of M2 macrophage-related genes for establishing a prognostic model in pancreatic cancer: FCGR3A as key gene

    ZHEN WANG1, JUN FU1, SAISAI ZHU1, HAODONG TANG2, KUI SHI1, JIHUA YANG3, MENG WANG3, MENGGE WU1, DUNFENG QI1,*

    Oncology Research, Vol.32, No.12, pp. 1851-1866, 2024, DOI:10.32604/or.2024.055286 - 13 November 2024

    Abstract Background: Pancreatic ductal adenocarcinoma (PDAC) has a rich and complex tumor immune microenvironment (TIME). M2 macrophages are among the most extensively infiltrated immune cells in the TIME and are necessary for the growth and migration of cancers. However, the mechanisms and targets mediating M2 macrophage infiltration in pancreatic cancer remain elusive. Methods: The M2 macrophage infiltration score of patients was assessed using the xCell algorithm. Using weighted gene co-expression network analysis (WGCNA), module genes associated with M2 macrophages were identified, and a predictive model was designed. The variations in immunological cell patterns, cancer mutations, and… More > Graphic Abstract

    Identification of M2 macrophage-related genes for establishing a prognostic model in pancreatic cancer: <i>FCGR3A</i> as key gene

  • Open Access

    ARTICLE

    A Deep Learning Framework for Mass-Forming Chronic Pancreatitis and Pancreatic Ductal Adenocarcinoma Classification Based on Magnetic Resonance Imaging

    Luda Chen1, Kuangzhu Bao2, Ying Chen2, Jingang Hao2,*, Jianfeng He1,3,*

    CMC-Computers, Materials & Continua, Vol.79, No.1, pp. 409-427, 2024, DOI:10.32604/cmc.2024.048507 - 25 April 2024

    Abstract Pancreatic diseases, including mass-forming chronic pancreatitis (MFCP) and pancreatic ductal adenocarcinoma (PDAC), present with similar imaging features, leading to diagnostic complexities. Deep Learning (DL) methods have been shown to perform well on diagnostic tasks. Existing DL pancreatic lesion diagnosis studies based on Magnetic Resonance Imaging (MRI) utilize the prior information to guide models to focus on the lesion region. However, over-reliance on prior information may ignore the background information that is helpful for diagnosis. This study verifies the diagnostic significance of the background information using a clinical dataset. Consequently, the Prior Difference Guidance Network (PDGNet)… More >

  • Open Access

    ARTICLE

    Neural Wiskott-Aldrich syndrome protein (N-WASP) promotes distant metastasis in pancreatic ductal adenocarcinoma via activation of LOXL2

    HYUNG SUN KIM1,#, YUN SUN LEE2,#, SEUNG MYUNG DONG3, HYO JUNG KIM1, DA EUN LEE2, HYEON WOONG KANG2, MYEONG JIN KIM2, JOON SEONG PARK1,*

    Oncology Research, Vol.32, No.4, pp. 615-624, 2024, DOI:10.32604/or.2024.044029 - 20 March 2024

    Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive solid malignancies. A specific mechanism of its metastasis has not been established. In this study, we investigated whether Neural Wiskott-Aldrich syndrome protein (N-WASP) plays a role in distant metastasis of PDAC. We found that N-WASP is markedly expressed in clinical patients with PDAC. Clinical analysis showed a notably more distant metastatic pattern in the N-WASP-high group compared to the N-WASP-low group. N-WASP was noted to be a novel mediator of epithelial-mesenchymal transition (EMT) via gene expression profile studies. Knockdown of N-WASP in pancreatic cancer cells… More > Graphic Abstract

    Neural Wiskott-Aldrich syndrome protein (N-WASP) promotes distant metastasis in pancreatic ductal adenocarcinoma via activation of LOXL2

  • Open Access

    REVIEW

    Stem cell technology for antitumor drug loading and delivery in oncology

    FRANCESCO PETRELLA*, ENRICO MARIO CASSINA, LIDIA LIBRETTI, EMANUELE PIRONDINI, FEDERICO RAVEGLIA, ANTONIO TUORO

    Oncology Research, Vol.32, No.3, pp. 433-437, 2024, DOI:10.32604/or.2023.046497 - 06 February 2024

    Abstract The main aim of antineoplastic treatment is to maximize patient benefit by augmenting the drug accumulation within affected organs and tissues, thus incrementing drug effects and, at the same time, reducing the damage of non-involved tissues to cytotoxic agents. Mesenchymal stromal cells (MSC) represent a group of undifferentiated multipotent cells presenting wide self-renewal features and the capacity to differentiate into an assortment of mesenchymal family cells. During the last year, they have been proposed as natural carriers for the selective release of antitumor drugs to malignant cells, thus optimizing cytotoxic action on cancer cells, while More >

  • Open Access

    ARTICLE

    Comprehensive analysis reveals an arachidonic acid metabolism-related gene signature in patients with pancreatic ductal adenocarcinoma

    HUILI ZHU1, LINA XIAO1, XIA YIN1, SHIBING XIANG1, CHUNHUI WANG2,*

    BIOCELL, Vol.46, No.10, pp. 2241-2256, 2022, DOI:10.32604/biocell.2022.020389 - 13 June 2022

    Abstract Pancreatic ductal adenocarcinoma (PDAC) is highly heterogeneous, making its prognosis prediction difficult. The arachidonic acid (AA) cascade is involved in carcinogenesis. Therefore, the metabolic enzymes of the AA cascade consist of lipoxygenases (LOXs), phospholipase A2s (PLA2s), and cyclooxygenases (COXs) along with their metabolic products, including leukotrienes. Nevertheless, the prognostic potential of AA metabolism-associated PDAC has not been explored. Herein, the mRNA expression patterns and the matching clinical information of individuals with PDAC were abstracted from online data resources. We employed the LASSO Cox regression model to develop a multigene clinical signature in the TCGA queue.… More >

  • Open Access

    ARTICLE

    Phosphoglycerate Mutase 1 (PGAM1) Promotes Pancreatic Ductal Adenocarcinoma (PDAC) Metastasis by Acting as a Novel Downstream Target of the PI3K/Akt/mTOR Pathway

    Xinlu Liu, Xiaodong Tan, Peng Liu, Yunhao Wu, Songying Qian, Xiaobo Zhang

    Oncology Research, Vol.26, No.7, pp. 1123-1131, 2018, DOI:10.3727/096504018X15166223632406

    Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive tumors known, with an overall 5-year survival rate of less than 6% due to early local invasion and distant metastasis. Exploring suitable therapeutic targets associated with invasion and metastasis is required for improving the prognosis of PDAC. In this study, we investigated the role of the glycolytic enzyme phosphoglycerate mutase 1 (PGAM1) in PDAC. PGAM1 expression was examined in tissue samples of 54 PDAC patients using immunohistochemistry, and the correlation between clinicopathological expression and PGAM1 expression was determined. A survival curve was generated using the… More >

Displaying 1-10 on page 1 of 6. Per Page